What Happened
On September 22, 2026, the registrational Phase 3 ZUPREME program launched for petrelintide, a once-weekly amylin analogue. The program spans three trials and roughly 7,000 participants, with a primary endpoint of body-weight change at week 64. Its launch marks a major step for the amylin class and for the strategy of pursuing amylin signaling on its own, rather than in combination with incretins.
What Petrelintide Is
Petrelintide is a once-weekly amylin analogue developed by Zealand Pharma, which is partnered with Roche on the program. That partnership attribution is worth stating clearly: petrelintide is a Zealand Pharma compound, developed with Roche. It targets the amylin receptor, a pathway distinct from the GLP-1 and GIP receptors that anchor the incretin-based drugs dominating the field. The once-weekly dosing places it on a familiar cadence for the category, while its amylin-alone mechanism sets it apart from both the incretin agents and the combination approaches that pair amylin with GLP-1.
The ZUPREME Program
The registrational Phase 3 ZUPREME program is substantial. It includes three trials spanning roughly 7,000 participants, with a primary endpoint of body-weight change at week 64. Registrational programs are those designed to support regulatory approval, so ZUPREME represents petrelintide's bid to establish the evidence needed for potential authorization. The scale, three trials and thousands of participants, reflects the rigor expected of late-stage obesity development and the seriousness with which the amylin-alone approach is being tested.
The Amylin-Alone Rationale
What makes petrelintide particularly interesting is its status as an amylin-alone approach. Most of the field's attention has centered on GLP-1 and multi-receptor agents. Petrelintide instead tests whether amylin signaling on its own can deliver meaningful outcomes. Two motivations drive that exploration: tolerability and possible lean-mass preservation relative to incretin drugs.
The lean-mass question is a notable one. Weight loss with incretin agents includes some loss of lean mass alongside fat, and there is research interest in whether amylin-based approaches might preserve lean mass more effectively. ZUPREME is positioned to help address whether that potential holds up in a large, controlled setting, and its size gives it the statistical footing to examine such secondary questions alongside the primary weight endpoint.
Petrelintide joins a widening amylin field that includes Novo Nordisk's amycretin and cagrilintide and Ascletis's ASC36, among others. Within that field, petrelintide's once-weekly, amylin-alone profile gives it a distinct position, testing the pathway in relative isolation rather than in combination. That makes ZUPREME an unusually clean test of what amylin signaling can do without an incretin partner, which is part of why the program is closely watched.
What It Means
The ZUPREME launch elevates petrelintide to one of the most advanced amylin-alone programs in obesity. Its outcomes will inform whether amylin signaling can stand on its own as an obesity mechanism and whether the tolerability and lean-mass hypotheses surrounding the class translate into measurable advantages. For the broader amylin field, the results will be an important reference point regardless of the direction they take.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.